Zacks Investment Research Upgrades Ekso Bionics Holdings, Inc. (EKSO) to “Buy”
Zacks Investment Research upgraded shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) from a hold rating to a buy rating in a research report report published on Wednesday morning. They currently have $1.50 target price on the stock.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, B. Riley reaffirmed a buy rating and issued a $4.00 target price on shares of Ekso Bionics Holdings in a report on Wednesday, May 10th.
Shares of Ekso Bionics Holdings (NASDAQ:EKSO) opened at 1.25 on Wednesday. The firm’s market capitalization is $32.24 million. Ekso Bionics Holdings has a 12-month low of $0.99 and a 12-month high of $6.38. The company has a 50-day moving average price of $1.77 and a 200 day moving average price of $2.46.
COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/08/27/zacks-investment-research-upgrades-ekso-bionics-holdings-inc-ekso-to-buy.html.
In other news, insider Russ Angold sold 221,746 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $1.55, for a total value of $343,706.30. Following the completion of the transaction, the insider now directly owns 400,678 shares of the company’s stock, valued at $621,050.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 259,352 shares of company stock valued at $399,373. 7.10% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in EKSO. Vanguard Group Inc. raised its position in Ekso Bionics Holdings by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares in the last quarter. National Planning Corp raised its position in Ekso Bionics Holdings by 116.2% in the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after buying an additional 126,000 shares in the last quarter. Intellectus Partners LLC raised its position in Ekso Bionics Holdings by 5.3% in the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares in the last quarter. Carl Domino Inc raised its position in Ekso Bionics Holdings by 74.7% in the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after buying an additional 35,088 shares in the last quarter. Finally, Independence Advisors LLC acquired a new position in Ekso Bionics Holdings during the second quarter valued at about $1,840,000. 5.03% of the stock is owned by institutional investors.
About Ekso Bionics Holdings
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.